SARS-CoV-2

E335284

SARS-CoV-2 is the novel coronavirus responsible for the global outbreak of the respiratory disease COVID-19.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (6)

Statements (54)

Predicate Object
instanceOf betacoronavirus
coronavirus
enveloped virus
positive-sense single-stranded RNA virus
zoonotic virus
abbreviation SARS-CoV-2 self-linksurface differs
surface form: SARS2
associatedDisease severe acute respiratory syndrome
BaltimoreClassification Group IV
biosafetyLevel BSL-3
canCause acute respiratory distress syndrome
loss of smell
loss of taste
multi-organ failure
pneumonia
causes COVID-19 pandemic
surface form: COVID-19
declaredPublicHealthEmergencyBy World Health Organization
family Riboviria
surface form: Coronaviridae
firstDetectedIn Wuhan
firstDetectedInCountry China
firstDetectionDate 2019-12
fullName SARS-CoV-2 self-linksurface differs
surface form: Severe acute respiratory syndrome coronavirus 2
genomeLength approximately 29.9 kilobases
genomeSegmentation non-segmented
genomeSense positive-sense
genomeStrandedness single-stranded
genomeType RNA
genus Betacoronavirus
hasProtein accessory proteins
envelope protein
membrane protein
non-structural proteins
nucleocapsid protein
spike glycoprotein
hasVariant Alpha variant
Beta variant
Delta variant
Gamma variant
Omicron variant
host bat
human
inactivatedBy alcohol-based disinfectant
soap
order Nidovirales
parentTaxon SARS-CoV-2 self-linksurface differs
surface form: Severe acute respiratory syndrome-related coronavirus
preventedBy COVID-19 vaccines
surface form: COVID-19 vaccine
primaryInfectionSite respiratory tract
receptorUsedForEntry ACE2
relatedTo MERS-CoV
SARS-CoV
subfamily Nidovirales
surface form: Orthocoronavirinae
taxonRank species
transmissionRoute aerosols
contact with contaminated surfaces
respiratory droplets

Referenced by (16)

Full triples — surface form annotated when it differs from this entity's canonical label.

COVID-19 pandemic hasCauseAgent SARS-CoV-2
COVID-19 vaccines targetPathogen SARS-CoV-2
human adenovirus serotype 26 (Ad26) usedInVaccineAgainst SARS-CoV-2
subject surface form: human adenovirus serotype 26
ENSEMBLE trial targetPathogen SARS-CoV-2
Ad26.COV2.S targetVirus SARS-CoV-2
Cepheid developsTestFor SARS-CoV-2
SARS-CoV-2 parentTaxon SARS-CoV-2 self-linksurface differs
this entity surface form: Severe acute respiratory syndrome-related coronavirus
SARS-CoV-2 abbreviation SARS-CoV-2 self-linksurface differs
this entity surface form: SARS2
SARS-CoV-2 fullName SARS-CoV-2 self-linksurface differs
this entity surface form: Severe acute respiratory syndrome coronavirus 2
Pfizer–BioNTech targetPathogen SARS-CoV-2
this entity surface form: SARS‑CoV‑2
Delta variant causes SARS-CoV-2
this entity surface form: COVID-19
Delta variant virusType SARS-CoV-2
Delta variant belongsToSpecies SARS-CoV-2
this entity surface form: Severe acute respiratory syndrome coronavirus 2
Sinovac targetVirus SARS-CoV-2
subject surface form: CoronaVac
Omicron variant parentTaxon SARS-CoV-2
Omicron variant belongsToSpecies SARS-CoV-2
this entity surface form: Severe acute respiratory syndrome coronavirus 2